JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pauleit, D.
Right arrow Articles by Langen, K.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pauleit, D.
Right arrow Articles by Langen, K.-J.
Journal of Nuclear Medicine Vol. 45 No. 3 374-381
© 2004 by Society of Nuclear Medicine


Clinical Investigations

Comparison of O-(2-18F-Fluoroethyl)-L-Tyrosine PET and 3-123I-Iodo-{alpha}-Methyl-L-Tyrosine SPECT in Brain Tumors

Dirk Pauleit, MD1,2, Frank Floeth, MD3, Lutz Tellmann, BSc4, Kurt Hamacher, PhD5, Hubertus Hautzel, MD1,2, Hans-W. Müller, MD2, Heinz H. Coenen, PhD5 and Karl-J. Langen, MD4

1 Clinic for Nuclear Medicine, Research Center Jülich, Jülich, Germany
2 Department of Nuclear Medicine, Heinrich-Heine-University, Düsseldorf, Germany
3 Department of Neurosurgery, Heinrich-Heine-University, Düsseldorf, Germany
4 Institute of Medicine, Research Center Jülich, Jülich, Germany
5 Institute of Nuclear Chemistry, Research Center Jülich, Jülich, Germany

The aim of this study was to compare PET with O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) and SPECT with 3-123I-iodo-{alpha}-methyl- L-tyrosine (123I-IMT) in patients with brain tumors. Methods: Twenty patients with a suspected brain tumor were investigated by 18F-FET PET, 123I-IMT SPECT, and MRI within 3 wk. Region-of-interest analyses were performed on coregistered PET/SPECT/MRI images and the tumor-to-brain ratio (TBR), muscle-to-brain ratio (MBR), cerebellum-to-brain ratio (CerBR), and sinus-to-brain ratio (SBR) were calculated. In addition, the presence of tumor and the discrimination of anatomic structures on 18F-FET PET and 123I-IMT SPECT images were visually determined by 3 observers who were unaware of clinical data. Results: The TBR of 18F-FET and 123I-IMT uptake in cerebral tumors showed a highly significant correlation (r = 0.96; P < 0.001). In the visual analysis for the presence or absence of tumors, no differences for 123I-IMT SPECT and 18F-FET PET were found in 19 of 20 patients; in one patient a low-grade glioma was only identified on 18F-FET PET images but not on 123I-IMT SPECT images. The contrast between tumor and normal brain was significantly higher in 18F-FET PET (TBR, 2.0 ± 0.9) than in 123I-IMT SPECT (TBR, 1.5 ± 0.5). The discrimination of anatomic structures yielded a significantly better score on 18F-FET PET images (rating score, 2.6 ± 0.9) compared with 123I-IMT SPECT images (rating score, 1.7 ± 0.9). The uptake of 18F-FET in the muscles was significantly higher compared with 123I-IMT (MBR 18F-FET, 1.4 ± 0.3; MBR 123I-IMT, 0.6 ± 0.2; P < 0.001) and 18F-FET demonstrated a significantly higher blood-pool radioactivity than 123I-IMT (SBR 18F-FET, 1.3 ± 0.2; SBR 123I-IMT, 0.8 ± 0.2; P < 0.001). Conclusion: The significant correlation of the TBRs of 18F-FET and 123I-IMT indicates that clinical experiences of brain tumor diagnostics with 123I-IMT SPECT might be valid for 18F-FET PET although substantial differences of the physiologic behavior were identified in extracerebral tissue. As 18F-FET PET allows improved discrimination of anatomic structures and the tumor-to-brain contrast was significantly superior compared with 123I-IMT SPECT scans, the results are encouraging for further evaluation of 18F-FET for imaging brain tumors.

Key Words: O-(2-18F-fluoroethyl)-L-tyrosine • 3-123I-iodo-{alpha}-methyl-L-tyrosine • PET • SPECT • brain tumor




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al.
Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study
Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. Pauleit, G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H. H. Coenen, and K.-J. Langen
PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in Peripheral Tumors: First Clinical Results
J. Nucl. Med., March 1, 2005; 46(3): 411 - 416.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
K.-J. Langen and S. Broer
Molecular Transport Mechanisms of Radiolabeled Amino Acids for PET and SPECT
J. Nucl. Med., September 1, 2004; 45(9): 1435 - 1436.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.